Abbott Spins Off $8.5B Nutrition, Fish Oil Brain Claims Challenged

Abbott is freeing its $8.5B nutrition division — including Ensure and Pedialyte — as a standalone public company. And a landmark clinical trial just dealt a serious blow to fish oil's brain health positioning. In this episode: Abbott is spinning out its nutrition division — home to Ensure and Pedialyte — into an independent publicly traded company generating approximately $8.5 billion in annual sales, giving it freedom to pursue its own marketing and commercial strategy. A rigorous two-year clinical trial confirmed fish oil successfully raised omega-3 levels in the brain but produced zero measurable improvement in memory or cognitive protection compared to controls, directly challenging one of the supplement industry's most valuable marketing platforms. Doctors and regulators are raising flags as growing numbers of GLP-1 drug users stack dietary supplements alongside their medication, with regulators in multiple markets actively exploring new rules to address unsupported claims targeting this population. Cymbiotika, which has sold 200 million liposomal sachets, is expanding into the beauty supplement market, using its liposomal delivery technology and bioavailability credentials as its core differentiator in an increasingly crowded ingestible beauty space. The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day. Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us. Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily